Altamira Therapeutics Achieves Successful DNA Delivery with Nanoparticle Technology
Altamira Therapeutics Ltd. has successfully demonstrated efficient DNA delivery using its xPhore™ nanoparticle technology in in vitro experiments. The results showed effective transfection of cells and reliable protein expression, highlighting the potential for applications in DNA vaccines, gene editing, and protein replacement therapies. The technology will be offered to biotech and pharmaceutical partners under the GenePhore™ label. No details were provided regarding future presentations or publications of these results.
Altamira Therapeutics Ltd. has announced successful results from in vitro experiments demonstrating efficient delivery of DNA molecules using its xPhore™ nanoparticle technology. The company reported effective transfection of cells and reliable expression of encoded proteins, showcasing the potential of its peptide-based delivery platform for large payloads like plasmid DNA. Altamira will offer this technology to biotech and pharmaceutical partners under the GenePhore™ label, targeting applications such as DNA vaccines, gene editing, and protein replacement therapies. The announcement did not specify if or when these results will be presented at a scientific conference or publication. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1096176) on November 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
